dc.contributor.author |
Li, Junhua |
|
dc.contributor.author |
Zhang, Cheng |
|
dc.contributor.author |
Xu, Hongrui |
|
dc.contributor.author |
Wang, Chao |
|
dc.contributor.author |
Dong, Ruibo |
|
dc.contributor.author |
Shen, Hui |
|
dc.contributor.author |
Zhuang, Xiaoxi |
|
dc.contributor.author |
Chen, Xiaoshan |
|
dc.contributor.author |
Li, Qiu |
|
dc.contributor.author |
Lu, Jibu |
|
dc.contributor.author |
Zhang, Maofeng |
|
dc.contributor.author |
Wu, Xishan |
|
dc.contributor.author |
Loomes, Kerry M |
|
dc.contributor.author |
Zhou, Yulai |
|
dc.contributor.author |
Zhang, Yan |
|
dc.contributor.author |
Liu, Jinsong |
|
dc.contributor.author |
Xu, Yong |
|
dc.coverage.spatial |
United States |
|
dc.date.accessioned |
2022-06-10T04:37:04Z |
|
dc.date.available |
2022-06-10T04:37:04Z |
|
dc.date.issued |
2022-04 |
|
dc.identifier.citation |
(2022). Journal of Medicinal Chemistry, 65(7), 5760-5799. |
|
dc.identifier.issn |
0022-2623 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/59723 |
|
dc.description.abstract |
Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The development of domain-selective BET inhibitors to separate efficacy and toxicity is urgently needed. Herein, we report a series of furo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one derivatives as novel BD2-selective BET inhibitors. The representative compound <b>8l</b> (XY153) potently bound to BRD4 BD2 with an half-maximum inhibitory concentration (IC<sub>50</sub>) value of 0.79 nM and displayed 354-fold selectivity over BRD4 BD1. Besides, <b>8l</b> exhibited 6-fold BRD4 BD2 domain selectivity over other BET BD2 domains. Compound <b>8l</b> displayed potent antiproliferative activity against multiple tumor cell lines, especially MV4-11 (IC<sub>50</sub> = 0.55 nM), while showing weak cytotoxicity against the normal lung fibroblast cell line. It highlights the safety profile of this series of BD2 inhibitors. <b>8l</b> also demonstrated good metabolic stability in vitro. These data indicate that <b>8l</b> may serve as a new and valuable lead compound for the development of potential therapeutics against acute myeloid leukemia (AML). |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
American Chemical Society (ACS) |
|
dc.relation.ispartofseries |
Journal of medicinal chemistry |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
Cell Line, Tumor |
|
dc.subject |
Cell Cycle Proteins |
|
dc.subject |
Nuclear Proteins |
|
dc.subject |
Transcription Factors |
|
dc.subject |
Antineoplastic Agents |
|
dc.subject |
Protein Domains |
|
dc.subject |
Hematology |
|
dc.subject |
Orphan Drug |
|
dc.subject |
Cancer |
|
dc.subject |
Rare Diseases |
|
dc.subject |
5.1 Pharmaceuticals |
|
dc.subject |
0304 Medicinal and Biomolecular Chemistry |
|
dc.subject |
0305 Organic Chemistry |
|
dc.subject |
1115 Pharmacology and Pharmaceutical Sciences |
|
dc.title |
Structure-Based Discovery and Optimization of Furo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1021/acs.jmedchem.2c00100 |
|
pubs.issue |
7 |
|
pubs.begin-page |
5760 |
|
pubs.volume |
65 |
|
dc.date.updated |
2022-05-02T05:55:13Z |
|
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
35333526 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/35333526 |
|
pubs.end-page |
5799 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Journal Article |
|
pubs.elements-id |
891822 |
|
pubs.org-id |
Science |
|
pubs.org-id |
Biological Sciences |
|
pubs.org-id |
Science Research |
|
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
|
dc.identifier.eissn |
1520-4804 |
|
pubs.record-created-at-source-date |
2022-05-02 |
|
pubs.online-publication-date |
2022-03-25 |
|